| fluoxetine / Generic mfg. |
ACTRN12614001243606: Comparison between the synergistic use of oral contraceptives and fluoxetine vs fluoxetine alone in the management of premenstrual syndrome |
|
|
| Recruiting | 3 | 210 | | | Cairo university , Cairo University | Premenstrual syndrome
| | | | |
| Terminated | 3 | | US | Fluoxetine | National Institute of Mental Health (NIMH) | Bipolar Disorder, Depression | | 09/00 | | |
NCT00018174: Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers |
|
|
| Completed | 3 | 247 | US | Fluoxetine, Behavioral group smoking cessation treatment, Placebo | US Department of Veterans Affairs, Eli Lilly and Company | Depression, Smoking | 01/03 | 01/05 | | |
| Completed | 3 | | US | Fluoxetine | University of Pittsburgh, National Institute of Mental Health (NIMH) | Anxiety Disorders | 05/03 | 05/03 | | |
NCT00000379: Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder (PTSD) |
|
|
| Completed | 3 | | US | Fluoxetine, EMDR | Boston University, National Institute of Mental Health (NIMH) | Stress Disorders, Post-Traumatic | | 12/03 | | |
NCT00006286: Treatment for Adolescents With Depression Study (TADS) |
|
|
| Completed | 3 | 432 | US | Fluoxetine, Psychotherapy | National Institute of Mental Health (NIMH) | Major Depressive Disorder, Depression | | 03/04 | | |
2004-004008-19: Efficacy and safety of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally for 8 weeks in out-patients with severe Major Depressive Disorder. A randomised double-blind, parallel groups, international study versus fluoxetine (20 mg/day with potential adjustment to 40 mg) with a double-blind extension period of 16 weeks. |
|
|
| Completed | 3 | 500 | Europe | S20098, Fluoxetine, S20098, Capsule, hard, PROZAC | Institut de Recherches Internationales Servier, Laboratorios Servier S.L. (For Spain only), SERVIER Research and Development ICTR (For United Kingdom only), INSTITUT DE RECHERCHES INTERNATIONALES SERVIER | Severe Major Depressive Disorder | | | | |
| Completed | 3 | 139 | US | Social Effectiveness Therapy for Children (SET-C), Fluoxetine, Pill Placebo | University of Central Florida, National Institute of Mental Health (NIMH) | Social Phobia | 09/06 | 09/06 | | |
| Completed | 3 | 494 | Canada, Europe, RoW | Quetiapine, Amitriptyline, Bupropion, Citalopram, Duloxetine, Escitalopram, Fluoxetine, Paroxetine, Sertraline, Venlafaxine | AstraZeneca | Major Depressive Disorder | | 04/07 | | |
| Completed | 3 | 523 | US | Continuation phase cognitive therapy, Continuation phase fluoxetine, Prozac, Continuation phase pill placebo, Acute phase cognitive therapy | University of Texas Southwestern Medical Center, National Institute of Mental Health (NIMH) | Depression | 07/08 | 07/08 | | |
ChiCTR-TRC-11001668: Efficacy and safety of agomelatine with flexible dose (25 mg/day with potential adjustment at 50 mg) given orally for 8 weeks in out-patients with Major Depressive Disorder. |
|
|
| Completed | 3 | 628 | | Oral Valdoxan, Agomelatine, 25 or 50mg, tablets ;Oral Prozac, Fluoxetine, 20 or 40mg capsules | Institut de Recherche Internationales Servier; Level of the institution：, Institut de Recherche Internationales Servier | Major Depressive Disorder | | | | |
| Completed | 3 | 158 | US | Fluoxetine, NPL-2008, Placebo | Neuropharm, Autism Speaks | Autistic Disorder | 01/09 | 01/09 | | |
| Terminated | 3 | 128 | US | Fluoxetine (prozac) | Neuropharm, Autism Speaks | Autistic Disorder | 04/09 | 04/09 | | |
NCT00074815: Treatment of Obsessive Compulsive Disorder in Children |
|
|
| Completed | 3 | 124 | US | Serotonin reuptake inhibitors management, Drug Name with Minimum-Maximum Dosage, Citalopram (Celexa)10-60;, Escitalopram (Lexapro)5-30;, Fluoxetine (Prozac) 10-60;, Fluvoxamine (Luvox)25-300;, Paroxetine (Paxil)10-50;, Paroxetine-CR (Paxil)10-50;, Clomipramine (Anafranil)25-200;, Sertraline (Zoloft) 25-200;, Venlafaxine (Effexor)25-225;, Venlafaxine XR (Effexor)37.5-225;, Cognitive behavioral therapy by a psychologist, Instructional cognitive behavioral therapy by a psychiatrist | Duke University, National Institute of Mental Health (NIMH) | Obsessive-Compulsive Disorder | 11/09 | 11/09 | | |
NCT02569970: Efficacy of Fluoxetine Against Seizure-induced Central Apneas |
|
|
| Completed | 3 | 70 | Europe | fluoxetine 20 mg, placebo 20 mg | Hospices Civils de Lyon | Epilepsy, Ictal/Post-ictal Hypoxemia | 12/10 | 01/15 | | |
NCT00115804: Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia |
|
|
| Completed | 3 | 6 | US | Fluoxetine, Prozac | University of Cincinnati | Juvenile Primary Fibromyalgia Syndrome (JPFS), Fibromyalgia | 02/11 | 02/11 | | |
| Completed | 3 | 463 | US, Canada, RoW | Placebo, fluoxetine, LY110140, Prozac, duloxetine, LY248686, Cymbalta | Eli Lilly and Company | Major Depressive Disorder | 02/11 | 09/11 | | |
| Completed | 3 | 337 | US, Europe, RoW | duloxetine, LY248686, Cymbalta, Placebo, fluoxetine, LY110140, Prozac | Eli Lilly and Company | Major Depressive Disorder | 03/11 | 10/11 | | |
ChiCTR-IIR-17012569: Phase III clinical trial of Ningweiyixing in treatment for mild and moderate depression (qi and yin deficiency) |
|
|
| Completed | 3 | 600 | | Ningyuyixing ;placebo ;fluoxetine | Xiyuan Hospital, China Academy ofChinese Medicine Science; Siji pharmaceutical co. LTD, Siji pharmaceutical co. LTD | Depression | | | | |
NCT00578669: Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms |
|
|
| Completed | 3 | 206 | US | Fluoxetine, Prozac, Dextrose | Butler Hospital, National Institute on Drug Abuse (NIDA) | Major Depressive Disorder, Nicotine Dependence, Depression | 07/13 | 11/13 | | |
NCT00958204: Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression |
|
|
| Completed | 3 | 134 | Canada | Light treatment, Negative ion therapy, Placebo, Fluoxetine | University of British Columbia, Canadian Institutes of Health Research (CIHR) | Major Depressive Disorder (MDD) | 02/14 | 05/14 | | |
NCT01808612: A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing |
|
|
| Completed | 3 | 513 | Japan | Fluoxetine, LY110140, Fluoxetine Hydrochloride, Prozac, Sarafem, Placebo | Eli Lilly and Company | Major Depressive Disorder | 07/14 | 07/14 | | |
| Terminated | 3 | 32 | RoW | Fluoxetine, Fluoxac, Placebo | Universidad Autónoma de Aguascalientes | Intracerebral Hemorrhage, Motor Impairment | 08/14 | 08/14 | | |
| Completed | 3 | 200 | Japan | Fluoxetine, LY110140, Fluoxetine Hydrochloride, Prozac, Sarafem | Eli Lilly and Company | Major Depressive Disorder | 03/15 | 03/15 | | |
| Completed | 3 | 340 | US, RoW | desvenlafaxine succinate sustained release, fluoxetine, placebo | Pfizer | Major Depressive Disorder | 03/15 | 03/15 | | |
NCT01687478: A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression |
|
|
| Terminated | 3 | 176 | RoW | Olanzapine, LY170053, Zyprexa, Fluoxetine, LY110140, Prozac, Placebo | Eli Lilly and Company | Treatment Resistant Depression | 11/15 | 11/15 | | |
| Ongoing | 3 | 3000 | Europe | fluoxetine 20mg. (trade name is Oxactin 20mg), Oxactin Capsules 20mg, Oxactin Capsules 20mg | University of Edinburgh, NHS Lothian, The Stroke Association | acute stroke | | | | |
2015-002181-23: Efficacy and safety of 2 doses of agomelatine (10mg, 25mg) given orally in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with moderate to severe Major Depressive Disorder. |
|
|
| Ongoing | 3 | 484 | Europe, RoW | Agomelatine, Fluoxetine, S20098, Film-coated tablet, Oral solution, Valdoxan, Fluoxetine | Institut de Recherche International Servier, ADIR | Major Depressive Disorder, Major Depressive Disorder, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Completed | 3 | 2944 | Canada, US, Europe, RoW | OPC-34712, Escitalopram, Lexapro, Fluoxetine, Prozac, Paroxetine CR, Paxil CR, Sertraline, Zoloft, Duloxetine, Cymbalta, Venlafaxine XR, Effexor XR | Otsuka Pharmaceutical Development & Commercialization, Inc. | Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders | 04/17 | 05/17 | | |
|
NCT02374567: Pharmacovigilance in Gerontopsychiatric Patients |
|
|
| Terminated | 3 | 407 | Europe | Phenobarbital, Phenytoin, Carbamazepine, Oxcarbazepine, Valproic Acid, Lamotrigine, Topiramate, Gabapentin, Levetiracetam, Pregabalin, Lacosamide, Clonazepam, Biperiden, Levomepromazine, Fluphenazine, Perphenazine, Perazine, Thioridazine, Haloperidol, Melperone, Pipamperone, Bromperidol, Benperidol, Sertindole, Ziprasidone, Flupentixol, Chlorprothixene, Zuclopenthixol, Fluspirilene, Pimozide, Clozapine, Olanzapine, Quetiapine, Sulpiride, Tiapride, Amisulpride, Prothipendyl, Risperidone, Aripiprazole, Paliperidone, Diazepam, Oxazepam, Lorazepam, Bromazepam, Clobazam, Alprazolam, Hydroxyzine, Buspirone, Chloral Hydrate, Flurazepam, Nitrazepam, Triazolam, Lormetazepam, Temazepam, Midazolam, Brotizolam, Zopiclone, Zolpidem, Zaleplon, Melatonin, Clomethiazole, Diphenhydramine, Promethazine, Imipramine, Clomipramine, Opipramol, Trimipramine, Amitriptyline, Nortriptyline, Doxepin, Maprotiline, Amitriptyline oxide, Fluoxetine, Citalopram, Paroxetine, Sertraline, Fluvoxamine, Escitalopram, Tranylcypromine, Moclobemide, Mianserin, Trazodone, Mirtazapine, Bupropion, Venlafaxine, Reboxetine, Duloxetine, Agomelatine, Pyritinol, Piracetam, Donepezil, Rivastigmine, Galantamine, Memantine, Nicergoline, Acamprosate, Lithium | Hannover Medical School | Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders | 06/17 | 06/17 | | |
NCT02488538: Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in Severe Premenstrual Syndrome |
|
|
| Unknown status | 3 | 300 | RoW | Combined oral contraceptives, Fluoxetine, Combined oral contraceptives placebo, Fluoxetine placebo, Daily record of severity of problems | Cairo University | Premenstrual Syndrome | 07/17 | | | |
NCT02562053: Does Adding Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome? |
|
|
| Unknown status | 3 | 300 | RoW | Fluoxetine, Combined oral contraceptives, Placebo 1, Placebo 2 | Cairo University | Premenstrual Syndrome | 09/17 | 09/17 | | |
NCT03087916: Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder |
|
|
| Recruiting | 3 | 660 | US | Placebo, Levomilnacipran ER, Fetzima, Fluoxetine, Prozac | Allergan | Major Depressive Disorder (MDD) | 03/18 | 03/18 | | |
| Completed | 3 | 473 | Canada, US | Vilazodone, Viibryd, Placebo, Fluoxetine, Prozac | Forest Laboratories | Major Depressive Disorder | 09/18 | 09/18 | | |
| Terminated | 3 | 1600 | | | Sir Charles Gairdner Hospital , National Health and Medical Research Council | Stroke | | | | |
| Unknown status | 3 | 340 | RoW | Support and Problem Solving Therapy, SPS, Cognitive Behavioural Case Management, CBCM, Fluoxetine, Anti-depressant medication, Placebo, Inactive Medicine, 3-monthly monitoring | Orygen, National Institute of Mental Health (NIMH), University of California, Davis, University of California, San Francisco | Psychotic Disorders, Personality Disorders, Clinical High Risk | 07/19 | 05/21 | | |
NCT02709746 / 2008-005354-20: Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD) |
|
|
| Completed | 3 | 784 | Europe, Canada, US, RoW | Vortioxetine 10 mg/day, Brintellix ®, Lu AA21004, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day, Placebo | H. Lundbeck A/S, Takeda | Depressive Disorder, Major | 07/19 | 07/19 | | |
NCT02431806: Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder |
|
|
| Completed | 3 | 552 | US | Placebo, Levomilnacipran, Fetzima, Fluoxetine, Prozac | Forest Laboratories | Major Depressive Disorder | 08/19 | 08/19 | | |
| Completed | 3 | 1500 | Europe | Fluoxetine, Placebo | Karolinska Institutet, The Swedish Research Council, Swedish Heart Lung Foundation, Stroke-Riksförbundet, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Hjärnfonden (The Swedish Brain foundation), The Swedish Medical Association | Stroke | 06/20 | 06/20 | | |
NCT03569475: Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder |
|
|
| Completed | 3 | 501 | US | Levomilnacipran ER, Fluoxetine, Placebo | Allergan | Major Depressive Disorder | 03/21 | 03/21 | | |
NCT02427334: Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome |
|
|
| Recruiting | 3 | 210 | RoW | Dienogest, Fluoxetine, Placebo | Cairo University | Premenstrual Syndrome | 12/21 | 12/21 | | |
NCT02709655 / 2008-005353-38: Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD) |
|
|
| Completed | 3 | 683 | Europe, Canada, US, RoW | Vortioxetine 10 mg/day, Brintellix ®, Lu AA21004, Vortioxetine 20 mg/day, Fluoxetine 20mg/day, Placebo | H. Lundbeck A/S, Takeda | Depressive Disorder, Major | 01/22 | 01/22 | | |
NCT03538691 / 2018-000601-22: A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder |
|
|
| Completed | 3 | 1149 | US | Brexpiprazole, OPC-34712, Rexulti, Antidepressant therapy | Otsuka Pharmaceutical Development & Commercialization, Inc. | Major Depressive Disorder | 07/22 | 07/22 | | |
NCT04676139: The Safety and Efficacy of Fluoxetine for Refractory Primary Mono-symptomatic Nocturnal Enuresis in Children |
|
|
| Recruiting | 3 | 100 | RoW | Fluoxetine, Placebo | Mansoura University | Nocturnal Enuresis | 10/22 | 12/22 | | |
NCT04727424: Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms |
|
|
| Recruiting | 3 | 7819 | RoW | Spirulin Platensis, Budesonide Powder, Fluvoxamine Maleate 100 MG [Luvox], Fluoxetine 20 MG, Budesonide powder, Placebo | Cardresearch, Cytel Inc., McMaster University, Fastgrants, Eiger BioPharmaceuticals, RainWater Foundation | Covid19, SARS-Associated Coronavirus | 06/24 | 07/24 | | |
| Active, not recruiting | 3 | 316 | US | Fluoxetine, Cognitive Behavioral Therapy (CBT) | Children's Hospital Los Angeles, Patient-Centered Outcomes Research Institute | Anxiety Disorders | 12/24 | 12/25 | | |
| Recruiting | 3 | 1500 | RoW | Healthy Activity Program (HAP), Antidepressant medication (fluoxetine) | Harvard Medical School (HMS and HSDM), Sangath, All India Institute of Medical Sciences, Bhopal, Vanderbilt University, Brigham and Women's Hospital, Centre for Addiction and Mental Health, Massachusetts General Hospital, Harvard School of Public Health (HSPH), National Institute of Mental Health (NIMH) | Depression, Depressive Disorder | 08/25 | 12/26 | | |
| Completed | 2/3 | 334 | US | Fluoxetine, Prozac, Venlafaxine, Effexor XR, Cognitive Behavioral Therapy (CBT), Citalopram, Celexa | University of Pittsburgh, National Institute of Mental Health (NIMH) | Depression | 03/07 | 03/07 | | |
NCT00080158: Treatment of Adolescent Suicide Attempters (TASA) |
|
|
| Completed | 2/3 | 120 | US | fluoxetine, sertraline, citalopram, escitalopram, bupropion, mirtazapine, venlafaxine, lithium, Cognitive Behavioral Therapy | New York State Psychiatric Institute, National Institute of Mental Health (NIMH) | Depression, Suicide, Attempted | | 06/07 | | |
NCT01269788: Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial |
|
|
| Completed | 2/3 | 144 | RoW | Fluoxetine, Omeprazole, placebo | Tehran University of Medical Sciences | Non-erosive Reflux Disease | 08/11 | 08/11 | | |
NCT05283954: Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea |
|
|
| Withdrawn | 2/3 | 954 | NA | Combination regimen: Fluoxetine, Prednisolone, Ivermectin, Combination regimen: Albendazole, Vitamin C | Oriol Mitja, National Department of Health, Papua New Guinea, Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | SARS-CoV2 Infection, COVID-19 | 06/22 | 07/22 | | |
NCT04780152: TDCS in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemic |
|
|
| Recruiting | 2/3 | 172 | RoW | Transcranial Direct Current Stimulation, TDCS, Anodal electric transcranial direct current stimulation, Placebo-simulation of transcranial direct current stimulation, Fluoxetine Tablets, Antidepressants | El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico | Major Depressive Disorder | 08/22 | 09/22 | | |
